Publications by authors named "Shimabukuro Michitomo"
Article Synopsis
- Deep brain stimulation (DBS) is a successful treatment for reducing resting tremors in Parkinson's disease (PD), but there’s a need for quick ways to measure its effectiveness during surgery.
- In a study involving 39 PD patients, researchers analyzed surface electromyography (sEMG) data to understand how DBS affects neuromuscular patterns and to identify predictive biomarkers that correlate with clinical outcomes.
- The findings indicated that DBS significantly altered various neuromuscular features, particularly reducing firing rate and amplitude, with three specific sEMG features showing strong correlations to clinical improvement, which helped develop an effective prediction model for treatment outcomes.
Article Synopsis
- Levodopa-induced dyskinesia (LID) is a frequent issue for people receiving long-term dopamine treatment for Parkinson's disease, leading to the need for understanding its underlying mechanisms.
- A study using a rat model identified a specific long noncoding RNA, NONRATT023402.2, whose levels decreased during the progression of Parkinson's disease and LID, alongside its target genes linked to inflammation.
- The findings suggest that NONRATT023402.2 might play a role in reducing the severity of dyskinesia through its inhibitory effects on related gene expressions.
Background: Parkinson's disease (PD) is a common movement disorder for which diagnosis mainly depends on the medical history and clinical symptoms. Exosomes are now considered an additional mechanism for intercellular communication, allowing cells to exchange proteins, lipids, and genetic material. Long noncoding (lnc) RNA in exosomes plays a critical role in many diseases, including neurodegenerative disease.
View Article and Find Full Text PDFObjective: To compare the efficacy of subthalamic nucleus (STN) and globus pallidus internus (GPi) deep brain stimulation (DBS) on reducing levodopa-induced dyskinesia (LID) in Parkinson's disease, and to explore the potential underlying mechanisms.
Methods: We retrospectively assessed clinical outcomes in 43 patients with preoperative LID who underwent DBS targeting the STN (20/43) or GPi (23/43). The primary clinical outcome was the change from baseline in the Unified Dyskinesia Rating Scale (UDysRS) and secondary outcomes included changes in the total daily levodopa equivalent dose, the drug-off Unified Parkinson Disease Rating Scale Part Ⅲ at the last follow-up (median, 18 months), adverse effects, and programming settings.
Positron emission tomography (PET) scan with tracer [F]-fluorodeoxy-glucose (F-FDG) is widely used to measure the glucose metabolism in neurodegenerative disease such as Idiopathic Parkinson's disease (IPD). Previous studies using F-FDG PET mainly focused on the motor or non-motor symptoms but not the severity of IPD. In this study, we aimed to determine the metabolic patterns of F-FDG in different stages of IPD defined by Hoehn and Yahr rating scale (H-Y rating scale) and to identify regions in the brain that play critical roles in disease progression.
View Article and Find Full Text PDF